# Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy

> **NCT00892112** · PHASE3 · COMPLETED · sponsor: **Prothya Biosolutions** · enrollment: 50 (actual)

## Conditions studied

- Myocardial Diseases
- Parvovirus B19, Human

## Interventions

- **DRUG:** Intravenous Immunoglobulins
- **DRUG:** plasma volume expander

## Key facts

- **NCT ID:** NCT00892112
- **Lead sponsor:** Prothya Biosolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00892112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00892112, "Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00892112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*